Cargando…
An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors
Rational: Tumor immunogenic cell death (ICD), induced by certain chemotherapeutic drugs such as doxorubicin (Dox), is a form of apoptosis potentiating a protective immune response. One of the hallmarks of ICD is the translocation of calreticulin to the cell surface acting as an 'eat me' si...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419059/ https://www.ncbi.nlm.nih.gov/pubmed/34522209 http://dx.doi.org/10.7150/thno.56936 |
_version_ | 1783748680796340224 |
---|---|
author | Abdel-Bar, Hend Mohamed Walters, Adam A Lim, Yau Rouatbi, Nadia Qin, Yue Gheidari, Fatemeh Han, Shunping Osman, Rihab Wang, Julie Tzu-Wen Al-Jamal, Khuloud T. |
author_facet | Abdel-Bar, Hend Mohamed Walters, Adam A Lim, Yau Rouatbi, Nadia Qin, Yue Gheidari, Fatemeh Han, Shunping Osman, Rihab Wang, Julie Tzu-Wen Al-Jamal, Khuloud T. |
author_sort | Abdel-Bar, Hend Mohamed |
collection | PubMed |
description | Rational: Tumor immunogenic cell death (ICD), induced by certain chemotherapeutic drugs such as doxorubicin (Dox), is a form of apoptosis potentiating a protective immune response. One of the hallmarks of ICD is the translocation of calreticulin to the cell surface acting as an 'eat me' signal. This manuscript describes the development of a stable nucleic acid-lipid particles (SNALPs) formulation for the simultaneous delivery of ICD inducing drug (Dox) with small interfering RNA (siRNA) knocking down CD47 (siCD47), the dominant 'don't eat me' marker, for synergistic enhancement of ICD. Methods: SNALPs loaded with Dox or siCD47 either mono or combinatory platforms were prepared by ethanol injection method. The proposed systems were characterized for particle size, surface charge, entrapment efficiency and in vitro drug release. The ability of the SNALPs to preserve the siRNA integrity in presence of serum and RNAse were assessed over 48 h. The in vitro cellular uptake and gene silencing of the prepared SNALPs was assessed in CT26 cells. The immunological responses of the SNALPs were defined in vitro in terms of surface calreticulin expression and macrophage-mediated phagocytosis induction. In vivo therapeutic studies were performed in CT26 bearing mice where the therapeutic outcomes were expressed as tumor volume, expression of CD4 and CD8 as well as in vivo silencing. Results: The optimized SNALPs had a particle size 122 ±6 nm and an entrapment efficiency > 65% for both siRNA and Dox with improved serum stability. SNALPs were able to improve siRNA and Dox uptake in CT26 cells with enhanced cytotoxicity. siCD47 SNALPs were able to knockdown CD47 by approximately 70% with no interference from the presence of Dox. The siCD47 and Dox combination SNALPs were able to induce surface calreticulin expression leading to a synergistic effect on macrophage-mediated phagocytosis of treated cells. In a tumor challenge model, 50% of mice receiving siCD47 and Dox containing SNALPs were able to clear the tumor, while the remaining animals showed significantly lower tumor burden as compared to either monotreatment. Conclusion: Therefore, the combination of siCD47 and Dox in a particulate system showed potent anti-tumor activity which merits further investigation in future clinical studies. |
format | Online Article Text |
id | pubmed-8419059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-84190592021-09-13 An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors Abdel-Bar, Hend Mohamed Walters, Adam A Lim, Yau Rouatbi, Nadia Qin, Yue Gheidari, Fatemeh Han, Shunping Osman, Rihab Wang, Julie Tzu-Wen Al-Jamal, Khuloud T. Theranostics Research Paper Rational: Tumor immunogenic cell death (ICD), induced by certain chemotherapeutic drugs such as doxorubicin (Dox), is a form of apoptosis potentiating a protective immune response. One of the hallmarks of ICD is the translocation of calreticulin to the cell surface acting as an 'eat me' signal. This manuscript describes the development of a stable nucleic acid-lipid particles (SNALPs) formulation for the simultaneous delivery of ICD inducing drug (Dox) with small interfering RNA (siRNA) knocking down CD47 (siCD47), the dominant 'don't eat me' marker, for synergistic enhancement of ICD. Methods: SNALPs loaded with Dox or siCD47 either mono or combinatory platforms were prepared by ethanol injection method. The proposed systems were characterized for particle size, surface charge, entrapment efficiency and in vitro drug release. The ability of the SNALPs to preserve the siRNA integrity in presence of serum and RNAse were assessed over 48 h. The in vitro cellular uptake and gene silencing of the prepared SNALPs was assessed in CT26 cells. The immunological responses of the SNALPs were defined in vitro in terms of surface calreticulin expression and macrophage-mediated phagocytosis induction. In vivo therapeutic studies were performed in CT26 bearing mice where the therapeutic outcomes were expressed as tumor volume, expression of CD4 and CD8 as well as in vivo silencing. Results: The optimized SNALPs had a particle size 122 ±6 nm and an entrapment efficiency > 65% for both siRNA and Dox with improved serum stability. SNALPs were able to improve siRNA and Dox uptake in CT26 cells with enhanced cytotoxicity. siCD47 SNALPs were able to knockdown CD47 by approximately 70% with no interference from the presence of Dox. The siCD47 and Dox combination SNALPs were able to induce surface calreticulin expression leading to a synergistic effect on macrophage-mediated phagocytosis of treated cells. In a tumor challenge model, 50% of mice receiving siCD47 and Dox containing SNALPs were able to clear the tumor, while the remaining animals showed significantly lower tumor burden as compared to either monotreatment. Conclusion: Therefore, the combination of siCD47 and Dox in a particulate system showed potent anti-tumor activity which merits further investigation in future clinical studies. Ivyspring International Publisher 2021-08-11 /pmc/articles/PMC8419059/ /pubmed/34522209 http://dx.doi.org/10.7150/thno.56936 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Abdel-Bar, Hend Mohamed Walters, Adam A Lim, Yau Rouatbi, Nadia Qin, Yue Gheidari, Fatemeh Han, Shunping Osman, Rihab Wang, Julie Tzu-Wen Al-Jamal, Khuloud T. An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors |
title | An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors |
title_full | An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors |
title_fullStr | An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors |
title_full_unstemmed | An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors |
title_short | An “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors |
title_sort | “eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419059/ https://www.ncbi.nlm.nih.gov/pubmed/34522209 http://dx.doi.org/10.7150/thno.56936 |
work_keys_str_mv | AT abdelbarhendmohamed aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT waltersadama aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT limyau aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT rouatbinadia aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT qinyue aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT gheidarifatemeh aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT hanshunping aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT osmanrihab aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT wangjulietzuwen aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT aljamalkhuloudt aneatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT abdelbarhendmohamed eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT waltersadama eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT limyau eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT rouatbinadia eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT qinyue eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT gheidarifatemeh eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT hanshunping eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT osmanrihab eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT wangjulietzuwen eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors AT aljamalkhuloudt eatmecombinatorynanoformulationforsystemicimmunotherapyofsolidtumors |